Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses | npj Vaccines
Frontiers | A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
Data Science and Digital Health at Janssen R&D - YouTube
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses | npj Vaccines
Vaccines | Free Full-Text | COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
AdventHealth begins recruiting participants for Phase 3 COVID-19 Investigational vaccine clinical trial | AdventHealth Research Institute
Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Briefing Document- Sponsor
Janssen Vaccine Technologies | Janssen EMEA
P00081 Modification to MCDC OTA No. W150KN-16-9-1002 BETWEEN JANSSEN PHARMACEUTICALS, INC. 1125 TRENTON-HARBOURTON ROAD TITUSVIL
What Providers Need To Know About Janssen COVID-19 Vaccine (Johnson & Johnson)
Latest COVID-19 vaccine based on technology tested for safety & immunogenicity in IMI Ebola projects | IMI Innovative Medicines Initiative
Current advances in the development of SARS-CoV-2 vaccines
Maintaining Safety with SARS-CoV-2 Vaccines | NEJM
J&J plans to test its COVID-19 vaccine in ages 12-18 soon | Reuters
J&J's COVID-19 Vaccine Generates Antibodies in Primates, Preclinical Data Shows | BioSpace
COVID-19 Vaccine Janssen, INN-Ad26.COV2-S, recombinant
AMENDMENT OF SOLICITATIONAVIODIFICATION OF CONTRACT I 89
Johnson & Johnson 'Pauses' COVID-19 Vaccine Trial Due To Unexplained Illness In Participant; Eli Lilly Reportedly Suspending Trial Of Antibody Treatment - Health Policy Watch
